In the IMpower133 trial, the authors conducted an exploratory biomarker analysis on the efficacy of atezolizumab based on the blood-based tumor mutational burden (bTMB) and PD-L1 expression on both tumor cells (TCs) and tumor-infiltrating immune cells (ICs) [16]. This evidence concerns the gene CD274 and neoplasm.